Tango Therapeutics (TNGX) just posted its Q1 2026 numbers, with revenue at US$0 million, a reported loss of US$45.5 million and EPS of US$0.32. This sets a stark backdrop for how the rest of the year might look. Over recent quarters, the company has seen revenue move from US$4.1 million in Q4 2024 to US$53.8 million in Q3 2025 and then to US$0 million in Q1 2026. EPS shifted from a loss of US$0.35 in Q4 2024 to EPS of US$0.14 in Q3 2025 before returning to a loss of US$0.32 in the latest quarter, leaving margins under pressure and putting more weight on the growth story ahead.

See our full analysis for Tango Therapeutics.

Next, it helps to set these headline results against the main stories investors follow around Tango, to see where the numbers support the narrative and where they start to challenge it.

TTM loss of US$107.2 million keeps profitability in focus

• On a trailing 12 month basis to Q1 2026, Tango reported total revenue of US$57.0 million and a net loss of US$107.2 million, with basic EPS at a loss of US$0.86, so the business is still firmly in loss making territory despite the revenue base.
• Bears often highlight that losses have grown at about 16.5% per year over the past five years and that the company is forecast to remain unprofitable over the next three years, and this TTM net loss of US$107.2 million supports their concern that the path to profitability is still distant.
  • At the same time, the TTM loss has narrowed compared with the earlier TTM figure of US$145.6 million in Q2 2025, which challenges the harshest bearish view that losses are simply accelerating without any sign of improvement.
  • The TTM basic EPS loss of US$0.86 in Q1 2026 is smaller than the US$1.32 TTM loss recorded in Q2 2025, so the earnings trend is not one way traffic in the direction that the more pessimistic narrative implies.

56.6% revenue growth forecast set against zero Q1 revenue

• Forecasts point to revenue growing at about 56.6% per year based on the trailing 12 month data, yet Q1 2026 revenue came in at US$0 million after TTM revenue of US$57.0 million, which makes the timing and consistency of that growth a key issue to watch.
• Supporters of a more bullish view often focus on that 56.6% revenue growth forecast as the main upside driver, and this sits in tension with the fact that the last two quarters reported US$0 million revenue.
  • The TTM revenue line remains positive at US$57.0 million, so the longer run base that those growth forecasts reference is still in place even though recent quarterly revenue has dropped to zero.
  • The contrast between zero quarterly revenue and a double digit TTM revenue base means the bullish story around growth rests heavily on future periods looking more like the past twelve months than the last quarter.

Results like these often raise the question of how much weight to put on the growth story versus the recent loss trend, so it can help to see how other investors are framing the same numbers before making any decisions about Tango.

Curious how numbers become stories that shape markets? Explore Community Narratives

Premium 10.6x P/B with recent shareholder dilution

• Tango trades on a P/B of 10.6x compared with 4.7x for peers and 2.4x for the wider US biotech industry, and shareholders have also seen substantial dilution over the past year, so existing holders are paying a clear premium while owning a smaller slice of the company than before.
• Critics argue this high P/B multiple is hard to justify given ongoing losses and dilution, and the current figures back several of those concerns.
  • The stock price of US$24.87 sits on top of a business that produced a TTM net loss of US$107.2 million and basic EPS loss of US$0.86, which leans toward the bearish view that investors are paying up for a company that is still in investment mode.
  • Substantial shareholder dilution in the past year means any future improvement in EPS from the current quarterly loss of US$0.32 per share has to work harder across a larger share count, a point that aligns closely with the bearish focus on capital structure risk.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Tango Therapeutics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If this mix of pressure and potential feels finely balanced, take a moment to review the numbers yourself and decide how convincing the story is. Then weigh that view against the 1 key reward and 3 important warning signs by checking the 1 key reward and 3 important warning signs.

See What Else Is Out There

Tango is still reporting sizeable losses, zero recent revenue and shareholder dilution while trading on a premium 10.6x P/B, which keeps risk firmly on the table.

If you want ideas where the balance of risk and reward might feel more comfortable right now, check out 67 resilient stocks with low risk scores to focus on companies with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.